{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:41:03Z","timestamp":1780083663853,"version":"3.54.0"},"reference-count":28,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.3960\/jslrt.56.28","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T20:59:16Z","timestamp":1466629156000},"page":"28-33","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma"],"prefix":"10.3960","volume":"56","author":[{"given":"Shinichi","family":"Makita","sequence":"first","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"},{"name":"Departments of Hematology National Cancer Center Hospital"},{"name":"Juntendo University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Fuji","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniko","family":"Takano","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Inoue","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Ito","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinuko","family":"Tajima","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Okinaka","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"},{"name":"Departments of General Internal Medicine National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiko","family":"Kurosawa","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Tanosaki","sequence":"additional","affiliation":[{"name":"Departments of Blood Transfusion and Cellular Therapy National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"Departments of Hematology National Cancer Center Hospital"},{"name":"Juntendo University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Departments of Hematopoietic Stem Cell Transplantation National Cancer Center Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 The Non-Hodgkin\u2019s Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 89:3909-3918, 1997","DOI":"10.1182\/blood.V89.11.3909"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Thomas DA, O\u2019Brien S, Cortes J, Giles FJ, Faderl S, <i>et al<\/i>.: Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104:1624-1630, 2004","DOI":"10.1182\/blood-2003-12-4428"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Hoelzer D, G\u00f6kbuget N, Digel W, Faak T, Kneba M, <i>et al<\/i>.: Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99:4379-4385, 2002","DOI":"10.1182\/blood-2002-01-0110"},{"key":"4","unstructured":"4 Hunault M, Truchan-Graczyk M, Caillot D, Harousseau JL, Bologna S, <i>et al<\/i>.: Outcome of adult T-lymphoblastic lymphoma after acute lymphoblastic leukemia-type treatment: a GOELAMS trial. Haematologica 92:1623-1630, 2007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Cortelazzo S, Intermesoli T, Oldani E, Ciceri F, Rossi G, <i>et al<\/i>.: Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma. Ann Hematol 91:73-82, 2012","DOI":"10.1007\/s00277-011-1252-x"},{"key":"6","unstructured":"6 Azuma T, Tobinai K, Takeyama K, Shibata T, Hidaka M, <i>et al<\/i>.: Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402. Jpn J Clin Oncol 42:394-404, 2012"},{"key":"7","unstructured":"7 Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, <i>et al<\/i>.: Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster Group. J Clin Oncol 27:3363-3369, 2009"},{"key":"8","unstructured":"8 Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, <i>et al<\/i>.: Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86:1216-1230, 1999"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Levine JE, Harris RE, Loberiza FR Jr, Armitage JO, Vose JM, <i>et al<\/i>.: A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101:2476-2482, 2003","DOI":"10.1182\/blood-2002-05-1483"},{"key":"10","unstructured":"10 Lazarevic VLj, Remberger M, H\u00e4gglund H, Hallb\u00f6\u00f6k H, Juliusson G, <i>et al<\/i>.: Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: a retrospective study. Am J Hematol 86:709-710, 2011"},{"key":"11","unstructured":"11 Bouabdallah R, Xerri L, Bardou VJ, Stoppa AM, Blaise D, <i>et al<\/i>.: Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol 9:619-625, 1998"},{"key":"12","unstructured":"12 Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, <i>et al<\/i>.: High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation\/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19:2927-2936, 2001"},{"key":"13","unstructured":"13 van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, <i>et al<\/i>.: Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 100:299-307, 1996"},{"key":"14","unstructured":"14 American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th ed. Springer, New York, pp.393-430, 2002"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, <i>et al<\/i>.: Report of an International Workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol 17:1244, 1999","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, <i>et al<\/i>.: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"17","unstructured":"17 Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, <i>et al<\/i>.: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 16:1259-1266, 2002"},{"key":"18","unstructured":"18 Kim SW, Tanimoto TE, Hirabayashi N, Goto S, Kami M, <i>et al<\/i>.: Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. Blood 108:382-389, 2006"},{"key":"19","unstructured":"19 Sweetenham JW, Liberti G, Pearce R, Taghipour G, Santini G, <i>et al<\/i>.: High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation. J Clin Oncol 12:1358-1365, 1994"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Ellin F, Jerkeman M, Hagberg H, Relander T: Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry. Acta Oncol 53:927-934, 2014","DOI":"10.3109\/0284186X.2014.889850"},{"key":"21","unstructured":"21 DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, <i>et al<\/i>.: Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109:5136-5142, 2007"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Mai W, Meng H, Jin J, Wang L: Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol 77:445-447, 2006","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2889.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Crazzolara R, Bradstock KF, Bendall LJ: RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 5:727-728, 2009","DOI":"10.4161\/auto.5.5.8507"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, <i>et al<\/i>.: Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 113:6172-6181, 2009","DOI":"10.1182\/blood-2008-02-136762"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 G\u00f6kbuget N, Hoelzer D: Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 133-141, 2006","DOI":"10.1182\/asheducation-2006.1.133"},{"key":"26","unstructured":"26 Labopin M, Gorin NC, Polge E, Soci\u00e9 G, Gurman G, <i>et al<\/i>.: A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. Bone Marrow Transplant 49:376-381, 2014"},{"key":"27","unstructured":"27 Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, <i>et al<\/i>.: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95:416-421, 2000"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Bergeron C, Coze C, Segura C, Pacquement H, Gandemer V, <i>et al<\/i>.: Treatment of childhood T-cell lymphoblastic lymphomalong-term results of the SFOP LMT96 trial. Pediatr Blood Cancer 62:2150-2156, 2015","DOI":"10.1002\/pbc.25699"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/56\/1\/56_28\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T18:51:55Z","timestamp":1600800715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/56\/1\/56_28\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.56.28","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}